We are live on
!
Find out more
Kiniksa Pharmaceuticals
KNSA
KNSA
52 hedge funds and large institutions have $385M invested in Kiniksa Pharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 15 increasing their positions, 15 reducing their positions, and 12 closing their positions.
New
Increased
Maintained
Reduced
Closed
6% more capital invested
Capital invested by funds: $363M → $385M (+$22.3M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 15
5% less funds holding
Funds holding: 55 → 52 (-3)
12.36% less ownership
Funds ownership: 91.5% → 79.15% (-12%)
25% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 12
Holders
52
Holders Change
-3
Holders Change %
-5.45%
% of All Funds
1.16%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
9
Increased
15
Reduced
15
Closed
12
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.35M |
| 2 |
BlackRock
New York
|
+$4.06M |
| 3 |
DM
Deerfield Management
New York
|
+$1.4M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$926K |
| 5 |
SIM
Spark Investment Management
New York
|
+$417K |
